

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10556229
Filing Date	2005-11-09
First Named Inventor	Yevgeni BESIDSKI
Art Unit	1626
Examiner Name	Golam M. Shameem
Attorney Docket Number	101062-1P US

<b>U.S.PATENTS</b>						<b>Remove</b>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/GS/	1	3839347		1974-10-01	Fisher et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						<b>Add</b>
<b>U.S.PATENT APPLICATION PUBLICATIONS</b>						<b>Remove</b>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/GS/	1	20030158188	A1	2003-08-21	Lee et al.	
	2	20030149050	A1	2003-08-07	Jagtap et al.	
	3	20040092569	A1	2004-05-13	Demaine et al.	
	4	20040152690	A1	2004-08-05	Balan et al.	
↓	5	20060205802	A1	2006-09-14	Liu et al.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>			Application Number		10556229			
			Filing Date		2005-11-09			
			First Named Inventor			Yevgeni BESIDSKI		
			Art Unit			1626		
			Examiner Name			Golam M. Shameem		
			Attorney Docket Number			101062-1P US		

/GS/	6	20070066586	A1	2007-03-33	Tokumasu et al.	
/GS/	7	20080015222	A1	2008-01-17	Besidski et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/GS/	1	0882718	EP	B1	2005-08-31	Fujisawa Pharmaceuticals		<input type="checkbox"/>
	2	2300521	DE		1973-07-19	Merck & Co.		<input type="checkbox"/>
	3	02085866	WO	A1	2002-10-31	AstraZeneca AB		<input type="checkbox"/>
	4	03027076	WO	A2	2003-04-03	Solvay Pharmaceuticals		<input type="checkbox"/>
	5	04108712	WO	A1	2004-12-16	AstraZeneca AB		<input type="checkbox"/>
	6	05095327	WO	A1	2005-10-13	Ajinomoto Co., Inc.		<input type="checkbox"/>
	7	05021539	WO	A1	2005-03-10	Pfizer Japan, Inc.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>			Application Number		10556229			
			Filing Date		2005-11-09			
			First Named Inventor			Yevgeni BESIDSKI		
			Art Unit			1626		
			Examiner Name			Golam M. Shameem		
			Attorney Docket Number			101062-1P US		

/GS/	8	06033620	WO	A1	2006-03-30	AstraZeneca AB	<input type="checkbox"/>
	9	07073303	WO	A2	2007-06-28	AstraZeneca AB	<input type="checkbox"/>
↓	10	08/018827	WO	A1	2008-06-16	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/GS/	1	Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291482, BRN 838602 abstract and Kamel et al, J. Prakt. Chem., vol 31, 1966, pages 100-105	<input type="checkbox"/>
	2	Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291483 BRN 926470 abstract and Osman: Kolor. ERT., vol 11, 1969, page 118	<input type="checkbox"/>
	3	Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291484 BRN 311062 abstract & Pinnow; Wiskott: Chem. Ber., vol 32, 1899, page 900	<input type="checkbox"/>
	4	Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291485 BRN 189489 abstract & Foster: J. Chem. Soc., 1957, pages 4687-8	<input type="checkbox"/>
	5	Beilstein Institute for Organic Chemistry, Frankfurt-Main, Germany; XP002291490 BRN 326965 abstract & V. Walter; Kessler: J. Prak. Chem., vol 2, no. 74, 1906, page 198	<input type="checkbox"/>
↓	6	COLLINS et al., "Mucosal Tolerance to a Bacterial Superantigen Indicates a Novel AJ Toxic Shock", Infection and Immunity 70:2282-2287 (2002)	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number	10556229
		Filing Date	2005-11-09
		First Named Inventor	Yevgeni BESIDSKI
		Art Unit	1626
		Examiner Name	Golam M. Shameem
		Attorney Docket Number	101062-1P US

/GS/	7	LINDBERG, et al., "Long-Time Persistence of Superantigen-Producing Staphylococcus Aureus Strains in the Intestinal Microflora of Healthy Infants", Pediatric Research 48:741-747 (2000)	<input type="checkbox"/>
	8	Patent Abstracts of Japan vol 2000, no. 07, 29 September 2000 (2000-09-29) & JP 2000 095767 A (Takeda Chem Ind Ltd), 4 April 2000	<input type="checkbox"/>
	9	RUDIN, et al., "Staphylococcal Enterotoxin B and High Dose Phytohemagglutinin Induce a Th1- Skewed Response in Neonates Irrespective of Atopic Status at 2 Years of Age", Scandinavian Journal of Immunology 52:415-461 (2000)	<input type="checkbox"/>
	10	SASAKI, et al., "Prevention of collagen-induced arthritis with the superantigen Staphylococcal enterotoxin B", Pathophysiology 4:25-31 (1997)	<input type="checkbox"/>
	11	SOOS, et al., "Treatment PL/J mice with the superantigen, staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis", J Neuroimmunology 43:39-44 (1993)	<input type="checkbox"/>
	12	WILLITZER, H. et al., "Synthese und antivirale Wirsamkeit von substituierten 5-Ureido- und 5-Thioureidobenzimidazolderivaten" Pharmazie, VEB VERLAG VOLK und Gesundheit. Berlin, Germany vol 33, no. 1, January 1978 (1078-01), pages 30-38, XP002209435 ISSN: 0031-7144 English Abstract is cited as access no. 1978:424221	<input type="checkbox"/>
	13	STN International, File CAPLUS, accession no. 1978:424221, document no. 89:24221, Willitzer et al., "Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives", & Pharmazie (1978), 33(1) 30-8	<input type="checkbox"/>
	14	STN International File CAPLUS, accession no. 1958:50566, document no. 52:50566, R. Foster, "1-Ethyl-2-methyl-5-nitrobenzimidazole", & Journal of the Chem. Society, Abstracts (1957) 4687-8	<input type="checkbox"/>
	15	STN International, File HCPLUS, accession no. 2000:214835, document no. 132:265201, Takeda Chemical Industries LTD., "Preparation of imidazole derivatives as gonadotropin-releasing hormone antagonists", & JP, A2,200095767, 20000404	<input type="checkbox"/>
	16	STN International File CAPLUS accession no. 1967:46373, document no. 66:46373, Takahashi, S. et al., "Benzimidazole N-oxides. VII. Reactivity of 1,2-dimethylbenzimidazole 3-oxide" & Chem & Pharm Bulletin (1966), 14 (11), 1219-27	<input type="checkbox"/>
↓	17	STN International File CAPLUS, accession no. 1969:492626, doc no. 71:92626, Osman, M.A. "Benzimidazole derivatives as azoic diazo and coupling components", & Kolorisztikai Ertesito (1969) 11(5-6), 118-21	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number	10556229
		Filing Date	2005-11-09
		First Named Inventor	Yevgeni BESIDSKI
		Art Unit	1626
		Examiner Name	Golam M. Shameem
		Attorney Docket Number	101062-1P US

/GS/	18	STN Intl. CAPLUS, accession no. 1966:51996, document no. 64:51996, Kamel, M. et al., "New indazole and benzimidazole derivatives", Journal fuer Praktische Chemie (1966), 31(102), 100-8	<input type="checkbox"/>
	19	STN Intl. File Registry (Chemcats), compounds with Reg. Nos. 499119-26-5, 498538-36-6, 498535-73-2, 497242-15-6, 494202-99-2, 488804-38-2, 488095-08-5, 476326-10-0, 476325-77-6, 476281-13-7, 476279-49-9, 476275-91-9, 391218-48-7, 380905-60-2, 377757-95-4, 364625-75-2, 364054-61-5, 335397-26-7, 335397-24-5, 332899-59-9, 331840-20-1, 330466-04-1, 327971-85-7, 318512-58-2, 313535-67-0, 313509-05-6, 313508-99-5, 313367-31-6, 313275-92-2, 313275-91-1, 313275-90-0, 313275-89-7, 313275-88-6, 313275-87-5, 313241-54-2, 313241-53-1, +	<input type="checkbox"/>
	20	STN International , File Registry, see RN 743444-08-08, 13 Sep 2004	<input type="checkbox"/>
	21	Copy of non-final Office Action mailed on May 16, 2008, for application no. 10/557,806, AstraZeneca reference No. 101101-1P US	<input type="checkbox"/>
	22	Co-pending U.S. Application No. 11/836,221, Attorney Docket No. 102290-2 US/NS, filed on August 9, 2007	<input type="checkbox"/>
	23	Co-pending U.S. Application No. 11/614346, Attorney Docket No. 102022-2 US, filed on December 21, 2006	<input type="checkbox"/>
	24	Co-pending U.S. Publication No. 2008-0015222, Attorney Docket No. 101543-1P US, published on January 17, 2008	<input type="checkbox"/>
	25	Co-pending U.S. Publication No. 2006-0205802, Attorney Docket No. 101101-1P US, published on September 14, 2006	<input type="checkbox"/>
	26	Copy of non-final Office Action mailed on July 23, 2008 for application No. 10/557,806, AstraZeneca reference No. 101101-1P US	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	/Golam Shameem/	Date Considered	10/20/2008
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.